Researchers at MD Anderson Cancer Center believe that including clinical genomic profiling (CGP) into sarcoma management could result in more precise diagnosis and subclassification of the disease, based on results from a retrospective, observational, phase I study published in Oncotarget.
“Based on our findings, we believe that future studies in sarcomas should be guided by next-generation sequencing [NGS] and actionable alterations rather than histologic subtypes,” the researchers wrote. “Sarcomas are lacking in development of targeted therapy, but we demonstrate that there are myriad targets with novel therapeutic potential. We believe that personalization will shape future therapy in oncology. A rare and heterogeneous neoplasm like sarcoma would especially benefit from such a personalized approach.”
Groisberg R, Hong DS, Holla V, et al. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas [published online April 5, 2017]. Oncotarget. doi: 10.18632/oncotarget.16845.
... to read the full story